Introduction {#Sec1}
============

The Women\'s Health Initiative (WHI) double-blind, placebo-controlled clinical trial (CT) randomly assigned 36,282 postmenopausal women in the U.S. to 1,000 mg elemental calcium carbonate plus 400 IU of vitamin D~3~ daily or placebo, with average intervention period of 7.0 years. The trial was designed to test whether calcium plus vitamin D (CaD) supplementation in a population in which the use of these supplements was widespread would reduce hip fracture, and secondarily, total fracture and colorectal cancer. Even though CaD led to a significantly higher hip and total body bone mineral density than placebo (*P* \< 0.01), there was no compelling evidence for hip or total fracture risk reduction \[[@CR1]\]. Among women who adhered to study medications, however, there was a lower hip fracture incidence in the intervention group \[[@CR1]\], though this type of adherence-adjusted analysis involves additional modeling assumptions and lacks the reliability of the corresponding intention-to-treat analysis. Additional analyses led to reports of no clear evidence of benefit or harm for colorectal cancer \[[@CR2]\], breast cancer \[[@CR3]\], or other invasive cancer \[[@CR4]\], though the possibility of a breast cancer risk reduction among women using little or no personal calcium supplements was noted \[[@CR3]\]. Additional reports noted no clear evidence of influence on coronary heart disease (CHD) risk, defined in WHI and here as nonfatal myocardial infarction (MI) or CHD death \[[@CR5]\], and to the possibility of a reduction in total mortality \[[@CR6]\]. A modest elevation in urinary tract stone occurrence in the intervention group was also observed \[[@CR1], [@CR7]\].

The WHI trial has been criticized in that participating women were allowed to continue their personal use of calcium and/or vitamin D, in addition to taking study pills \[[@CR8]\]. Our perspective, as WHI investigators, is that the question of health risks and benefits associated with CaD supplementation, beyond the use of personal supplements, is of direct importance to postmenopausal women in the general population. We agree, however, that subset analyses restricted to women not taking personal supplements are of considerable interest from both etiologic and public health perspectives.

Bolland et al. \[[@CR8]\] reanalyzed WHI CaD trial data and reported an interaction (*P* = 0.04) in hazard ratio (HR) for "clinical MI" according to whether or not women were not using personal calcium supplements at baseline. A similar interaction was reported for combined clinical MI and stroke. These authors summarize that WHI trial data do not provide "definitive evidence" of an adverse effect of calcium and vitamin D on cardiovascular events, but they argue that data from other trials of calcium and vitamin D, or of calcium alone, in conjunction with WHI data, lead to the conclusion that calcium supplements with or without vitamin D increase the risk of cardiovascular events.

Essentially the same investigator group reanalyzed the WHI trial data further and reported \[[@CR9]\] an HR interaction for total cancer and invasive breast cancer, but not for hip or total fractures or total mortality, this time according to whether participating women were using personal supplements of either calcium or vitamin D at baseline. They interpreted these data as providing evidence of benefit for breast cancer and total cancer among women not taking personal supplements. Chlebowski et al. \[[@CR10]\] pointed out the need for a cautious interpretation in these subgroup analyses and described lack of support for a breast cancer risk reduction from other WHI data sources.

Here, we use WHI data resources to examine these topics further, with emphasis on the experience of women in the CT who were not using calcium or vitamin D supplements at baseline, as well as on the experience of the overall trial cohort. We include comparative analyses from the WHI Observational Study (OS), a prospective cohort study among 93,676 postmenopausal women drawn from the same catchment areas, for independent assessment of calcium and vitamin D health risks and benefits in WHI populations. Since OS women may have used these supplements for some years prior to WHI enrollment, these data have potential to augment trial information on the health effects of longer-term supplementation (e.g., 5 or more years). In fact, there have been several observational study reports of calcium supplementation in relation to cardiovascular disease \[[@CR11]--[@CR15]\]. While most of these report null or non-significant associations, the most recent of these reported a noteworthy increase in MI, but not stroke, incidence among the 3.6 % of an EPIC-Heidelberg cohort enrollees who were identified as calcium supplement users \[[@CR15]\].

These types of observational analyses can be difficult to interpret since nutritional supplement users tend to have quite different characteristics from non-users \[e.g., [@CR16]\], typically leaving uncertainty as to how completely confounding has been controlled. Also, common reasons for taking nutritional supplements include the belief that these preparations may prevent chronic diseases, such as cardiovascular disease, osteoporosis, and cancer \[[@CR16], [@CR17]\], raising the specter of "confounding by indication", which may tend to offset any "healthy supplement user" bias. Here, as in our earlier WHI combined CT and OS analyses of postmenopausal hormone therapy \[[@CR18]--[@CR23]\], our analyses allow for outcome-specific residual confounding in the OS. In effect, these combined CT and OS analyses allow an entirely separate overall HR from the OS versus the CT, so that OS data are used very conservatively to strengthen analysis of temporal HR variation patterns. The OS data also permit some examination of disease outcome associations for calcium and vitamin D supplementation separately.

Analyses presented here examine a range of clinical outcomes including fractures, invasive cancers, cardiovascular diseases, and total mortality. In each case, beyond overall supplementation effects, temporal associations of the HR with duration of supplementation, and the agreement of patterns between clinical trial and observational study, are examined. Urinary tract stone occurrence analyses in the CT, by personal supplement use category, are also presented to facilitate health benefit versus risk consideration.

Methods {#Sec2}
=======

Study populations and calcium and vitamin D supplementation {#Sec3}
-----------------------------------------------------------

A total of 36,282 postmenopausal women 50--79 years of age were randomized at 40 clinical sites to 1,000 mg calcium plus 400 IU vitamin D~3~ daily, given in two equal doses, versus placebo in the WHI CaD trial during 1994--99. Concurrent calcium supplementation was permitted, as was vitamin D supplementation up to 600 IU daily (later increased to 1,000 IU daily). Details of the study design \[[@CR24]\] and baseline characteristics \[[@CR1], [@CR2], [@CR25]\] have been presented. All participating women provided written informed consent.

No personal use of calcium or vitamin D supplements at baseline was reported by 42.2 % (15,302) of trial enrollees, whereas 43.5 % (15,796), 9.4 % (3,419), and 2.9 % (1,060) reported use of calcium plus vitamin D, calcium only, and vitamin D only, respectively, while baseline supplementation information was not available for 1.9 % (705) of women. Both single supplement and multivitamin/multimineral supplements were included in assessing personal use.

The companion WHI prospective Observational Study (OS) enrolled 93,676 postmenopausal women 50--79 years of age from the same catchment population during 1994--98. Baseline characteristics have been presented \[[@CR26]\]. To align with CT exclusionary criteria, we excluded 5,145 women with a baseline history of breast cancer, 15,511 women with no mammogram within 2 years prior to OS enrollment, 1,108 daily corticosteroid users, and 5,675 women who reported urinary tract stones at baseline, leaving 68,719 OS women. Of these, 34.3 % (23,561) reported no baseline supplementation with calcium or vitamin D, 49.9 % (34,257) reported use of both calcium and vitamin D, 12.5 % (8,576) reported calcium only, and 3.4 % (2,325) reported vitamin D only. Among the 42,833 baseline calcium users, the 5th, 10th, 25th, 50th, 75th, 90th, and 95th percentiles for daily dosage (milligrams per day) were 57, 143, 200, 571, 1,000, 1,305, and 1,640, respectively. We defined baseline calcium users in the OS as those taking ≥500 mg/day and excluded those consuming a lower dosage from our analysis. This cutpoint gives a user group having average daily dose similar to the 1,000 mg/day used in the WHI trial. Similarly, the corresponding percentiles for vitamin D (IU/day) were 125, 171, 400, 400, 400, 600, and 800 with 58 % of users reporting 400 IU/day. We defined vitamin D users in the OS as those taking ≥400 IU/day and excluded those taking a lower dosage from analysis. Following these exclusions, there were 15,476 calcium plus vitamin D users, 5,941 calcium-only users, and 1,914 vitamin D-only users at baseline in the OS which along with the previously mentioned 23,561 non-users of either supplement entails 46,892 OS women.

Data collection, follow-up, and outcome ascertainment {#Sec4}
-----------------------------------------------------

Clinical outcomes were self-reported semiannually in the CT and annually in the OS \[[@CR27]\]. Medical record documentation of these reports was obtained and diagnoses were confirmed at WHI clinical centers by physician adjudicators who were blinded to clinical trial randomization assignments. All clinical outcomes considered here, except certain fractures in the OS, were locally confirmed in this manner. Additionally, cases of coronary heart disease (CHD), stroke, and death were further adjudicated by a central committee in the CT, as were a fraction of such cases in the OS. Also, locally confirmed cases of breast cancer, colorectal cancer, and hip fracture in both the CT and OS were centrally reviewed and classified at the WHI clinical coordinating center. Fractures other than hip fractures were also adjudicated in the CT, as was the case for a small fraction of other fractures in the OS. Otherwise, self-report of fracture was relied on in the OS.

Information on adherence to assigned study pills was obtained semiannually in the CT through unused pill counts. Dietary supplement data were collected in both the CT and OS during in-person clinic visits. Women brought supplement bottles to the baseline clinic visit and to annual visits thereafter in the CT and to the baseline and 3-year clinic visit in the OS. A standardized interviewer-administered four-page form was used to collect information on single vitamin and mineral supplements and on multivitamin/multimineral use. Staff members directly transcribed the ingredients for each supplement and asked participants about the frequency (pills/week) and duration (months and years) of use for each supplement \[[@CR28], [@CR29]\].

The CaD trial ended as planned in March 2005 after an average intervention period of 7.0 years. Follow-up data from the OS are included here through 12/16/2004 to provide a comparable average follow-up period of 7.2 years. More recent health risk and benefit follow-up data from the trial are currently being consolidated for a separate presentation.

Standard procedures were used in the CT and OS to collect data on age, race/ethnicity, reproductive/gynecologic history, education, physical activity, medical history, family or personal history of cancer or coronary heart disease, diabetes mellitus, current health status, tobacco and alcohol use, and self-administered food frequency questionnaire. The WHI food frequency questionnaire (FFQ), in English or Spanish, involved 122 foods or food groups, 19 adjustment questions, 4 summary questions, and was designed to assess typical intakes over the preceding 3 months \[[@CR30]\]. Medication inventories were obtained at clinic visits, in the same manner as dietary supplements.

Statistical analysis {#Sec5}
--------------------

Principal data analyses focus on the estimation of hazard ratios corresponding to calcium and vitamin D supplementation, combined and separately, for each of the following clinical outcomes: hip fracture, total fracture, invasive colorectal cancer, invasive breast cancer, total invasive cancer (excluding non-melanoma skin cancer), total mortality, MI, CHD, total heart disease (CHD, revascularization, angina pectoris, congestive heart failure) , stroke (combined ischemic and hemorrhagic), and total cardiovascular disease (CVD) (total heart disease, stroke, carotid artery disease, peripheral vascular disease).

For each clinical outcome, the baseline hazard rate in the Cox regression model is stratified on cohort (CT versus OS), baseline age (5-year categories), and current use of postmenopausal estrogens or estrogens plus progestin defined as randomized to treatment if in the WHI hormone therapy trials \[[@CR24]\] and as current hormone therapy use at baseline otherwise. Prior use of estrogens or estrogens plus progestin, duration of any such prior use, and FFQ estimates of usual calcium and vitamin D consumption were also included as a modeled regression variables in the Cox model, in both the CT and the OS. Time from WHI enrollment is the "basic time variable" in these analyses. Hazard ratios were calculated separately for \<2, 2--5, and ≥5 years from initiation of supplementation to assess the temporal relationship between supplementation and any effects on clinical outcome. In the CT, time from supplement initiation is defined as time from randomization, whereas in the OS time from initiation of supplement use is defined as the sum of duration of use at baseline plus time from OS enrollment. Duration of use was defined as the longer of the two durations for women using both calcium and vitamin D supplements at baseline.

To further control confounding in the OS the hazard ratio regression model included an outcome-specific list of potential baseline confounding factors as is shown in Supplementary Table [1](#MOESM1){ref-type="media"}. For each outcome, this list included a linear term in age, an indicator of non-white ethnicity, body mass index (BMI) categorized variables for 25--29.9, for 30--34.9, and for ≥35.0 along with a linear term in BMI, and indicator variables for current or past cigarette smoking, in addition to other listed outcome-specific variables.

Analyses for each clinical outcome category were carried out using the entire CT enrollment, and also in the subsets of women who were not taking personal calcium or vitamin D supplements at baseline ("No personal supplements" subset) or were doing so ("Personal supplements" subset), and HR equality between these subsets was tested. For each analysis hazard ratios (HRs) and estimated 95 % confidence intervals (CIs) are presented according to years from supplement initiation (\<2, 2--5, and \>5) as a time-varying covariate. Significance levels (*P* values) are presented for a test of trend across the three time from initiation categories, coded as 0, 1, or 2, respectively. In addition, corresponding HR estimates from combined trial and observational data sets are given. These analyses allow for a residual confounding in the OS, by including a product term in the regression model between the OS versus CT indicator variable and the CaD user indicator variable. This variable allows the HR for CaD supplementation to differ by an overall multiplicative factor in the OS compared to the CaD trial, so that the OS data contribute to HR patterns with time from initiation but not to the absolute HR assessments in these combined analyses. With this modeling approach, overall HRs from combined CT and OS analyses are identical to those from the CT alone; but HR trend tests, which combine contributions from each cohort, may be strengthened by inclusion of the OS data. HRs and 95 % CIs for the entire follow-up period were calculated also, separately for the CT and OS.

Additional HR analyses in the CT censor the follow-up for women 6 months after a change from baseline in supplementation category, allowing the HRs to be interpreted in terms of duration of supplement use among adherent women, with continuing adherence defined as taking 80 % or more of assigned study medications in the preceding year. These adherence-adjusted analyses were conducted with and without inverse probability weighting in the Cox model, with weighting by estimated adherence probability, and with adherence probabilities estimated in a time-varying fashion using logistic regression models that include the Supplementary Table [1](#MOESM1){ref-type="media"} variables.

Analyses were also conducted separately according to decade of baseline age and according to prior history of CVD.

Nominal 95 % CIs are presented for HR parameters, and all *P* values presented are 2-sided.

Results {#Sec6}
=======

Table [1](#Tab1){ref-type="table"} shows number of cases for each clinical outcome and age-adjusted incidence rates for both cohorts according to randomization assignment in the CT and according to baseline use of calcium and vitamin D supplements in the OS. Incidence rates for most outcomes differed little between randomized groups in the CT.Table 1Age-adjusted annualized incidence rates in the WHI CaD trial and observational studyCaD TrialObservational StudyAll participantsNo personal supplements^a^Non-users of supplementsCalcium + Vitamin DCalcium onlyVitamin D onlyPlaceboCaDPlaceboCaDNumber of women18,10618,1767,5847,71823,56115,4765,9411,914Hip fractureCases19917580682121585526Age-adjusted incidence (%)^b^0.200.170.200.160.140.150.130.18Total fractureCases2,1582,1028708723,1722,344834290Age-adjusted incidence (%)^b^1.941.851.861.812.022.282.042.21Myocardial infarctionCases3904111671934332107740Age-adjusted incidence (%)^b^0.340.370.370.420.280.190.180.29Coronary heart diseaseCases4754992112295452529550Age-adjusted incidence (%)^b^0.420.450.470.510.350.230.220.36Total heart diseaseCases1,3631,4056426211,602762328132Age-adjusted incidence (%)^b^1.241.281.441.391.050.710.770.97StrokeCases3773621621844712539138Age-adjusted incidence (%)^b^0.350.330.370.420.310.230.210.27Total cardiovascular diseaseCases1,8101,8328138482,1871,069440181Age-adjusted incidence (%)^b^1.691.701.861.941.451.011.041.34Colorectal cancerCases154168776617488359Age-adjusted incidence (%)^b^0.130.150.160.140.110.080.080.06Breast cancerCases54652824920266551721060Age-adjusted incidence (%)^b^0.450.430.480.380.400.480.490.43Total invasive cancerCases1,4111,3666175531,7011,187474153Age-adjusted incidence (%)^b^1.211.161.281.111.071.111.121.12DeathCases8077443383311,240674266119Age-adjusted incidence (%)^b^0.720.670.750.720.780.610.610.84^a^No personal use of calcium or vitamin D at baseline^b^Adjusted to the 5-year baseline age distribution in the CaD trial

Table [2](#Tab2){ref-type="table"} provides HR estimates for fracture, and death according to years from CaD initiation, both for the CT as a whole and for the trial subset not using personal calcium or vitamin D at baseline; for the OS with outcome-specific confounding control; and for the combined CT and OS, with CT component including either the entire trial cohort or the subset not using personal supplements.Table 2Hazard ratios and 95 % confidence intervals for calcium plus vitamin D supplementation from the WHI CaD trial and the Observational Study according to years from supplement initiation: fractures and total deathsYears since CaD initiationCaD trialObservational studyCombined trial and OSAll participantsNo personal supplements^a^All participantsNo personal supplements^a^HR95 % CIHR95 % CIHR95 % CIHR95 % CIHR95 % CIHip fracture\<2**0**.**75**0.44,1.26**1**.**12**0.52,2.42**1**.**41**0.44,4.57**0**.**81**0.49,1.31**1**.**15**0.58,2.302--5**1**.**01**0.73,1.40**1**.**00**0.61,1.65**1**.**22**0.71,2.10**1**.**03**0.77,1.39**1**.**04**0.68,1.57\>5**0**.**82**0.61,1.12**0**.**62**0.38,1.00**0**.**84**0.66,1.07**0**.**78**0.59,1.03**0**.**65**0.44,0.98Trend test^b^0.960.130.140.430.02HR in OS/HR in trial^c^1.090.78,1.541.280.82,1.98Overall HR^d^**0**.**88**0.71, 1.08**0**.**86**0.62, 1.20**0**.**88**0.70, 1.11Total fracture\<2**0**.**96**0.86,1.08**0**.**91**0.76,1.10**0**.**89**0.61,1.31**0**.**95**0.85,1.06**0**.**90**0.76,1.062--5**0**.**94**0.86,1.03**0**.**97**0.84,1.12**1**.**05**0.91,1.22**0**.**95**0.87,1.03**0**.**98**0.87,1.11\>5**0**.**98**0.88,1.09**1**.**03**0.87,1.22**1**.**08**1.01,1.14**0**.**98**0.90,1.08**1**.**02**0.90,1.16Trend test^b^0.830.350.420.530.21HR in OS/HR in trial^c^1.090.99,1.211.050.92,1.20Overall HR^d^**0**.**96**0.90, 1.02**0**.**97**0.88, 1.07**1**.**07**1.01, 1.14Death\<2**0**.**73**0.56,0.96**0**.**68**0.44,1.06**1**.**49**0.79,2.83**0**.**80**0.62,1.04**0**.**86**0.58,1.272--5**0**.**87**0.75,1.02**0**.**87**0.68,1.11**0**.**85**0.61,1.18**0**.**87**0.76,1.01**0**.**89**0.72,1.09\>5**1**.**01**0.87,1.18**1**.**12**0.89,1.40**0**.**95**0.85,1.06**0**.**99**0.86,1.13**1**.**04**0.86,1.26Trend test^b^0.030.030.710.090.17HR in OS/HR in trial^c^0.970.82,1.150.920.74,1.14Overall HR^d^**0**.**91**0.83, 1.01**0**.**95**0.81, 1.11**0**.**95**0.85, 1.06^a^Women using personal calcium or vitamin D supplements at baseline in the CaD trial are excluded^b^Significance level (*P* value) for test of no HR trend across years from CaD initiation categories, coded as 0, 1, 2, respectively^c^Overall HR in the OS divided by that in the CaD trial. This ratio is used as a residual confounding bias correction factor in the OS, in combined trial and cohort study analyses^d^Overall HR is the hazard ratio estimate when the HR is assumed not to depend on years from CaD initiation

In women not taking supplements at baseline, the HR for hip fracture in the CT following 5 or more years of CaD supplementation versus placebo was 0.62 (95 % CI, 0.38 to 1.00). In combined analyses of CT and OS data (with residual confounding provision in the OS), the corresponding HR was 0.65 (95 % CI, 0.44 to 0.98) with evidence (*P* = 0.02) of HR trend with time from calcium and vitamin D initiation. Thus, there was evidence for lower hip fracture rates following some years of calcium plus vitamin D use in the subset of women not taking personal calcium or vitamin D supplements. This risk reduction was suggestive, but not clearly evident in the trial cohort as a whole (HR 0.82; 95 % CI, 0.61 to 1.12), or in combined trial and OS analyses. These combined overall CT and OS analyses provide some evidence for hip fracture benefit in the 5 or more years category (HR 0.78; 95 % CI, 0.59 to 1.03). Total fracture showed little evidence for association with CaD supplementation, with HRs from the OS tending to be larger than those from the CT.

To help interpret the hip fracture HRs, it can be noted that the FFQ 5th, 25th, 50th, 75th, and 95th percentiles for dietary calcium (milligram per day) were 291, 512, 738, 1,043, and 1,650, and for dietary vitamin D (IU/day), and were 47, 96, 149, 221, and 397 in the CT. Corresponding percentiles in the OS were 291, 571, 748, 1,074, and 1,693 for calcium, and 43, 93, 147, 225, and 407 for vitamin D, very similar to those in the CT. It is evident that personal supplement use of 500 mg/day or more calcium and 400 IU/day or more of vitamin D contributes a substantial fraction to the total consumption of these nutrients in study cohorts.

Table [2](#Tab2){ref-type="table"} also shows that total mortality was somewhat reduced in the first 2 years from randomization among women assigned to active treatment in the CT. This pattern was not evident in later years of follow-up, in corresponding OS analyses, or in combined CT and OS analyses.

Table [3](#Tab3){ref-type="table"} provides corresponding analyses for cardiovascular diseases. There was little evidence for an adverse influence of CaD supplementation on the risk for MI, CHD, total heart disease, stroke, or total cardiovascular disease, from either the CT or OS, or from their combined analysis. In fact, the OS data alone suggest a reduction in total heart disease risk and total cardiovascular disease risk among supplement users.Table 3Hazard ratios and 95 % confidence intervals for calcium plus vitamin D supplementation from the WHI CaD trial and Observational Study according to years from supplement initiation: cardiovascular diseasesYears since CaD initiationCaD trialObservational studyCombined trial and OSAll participantsNo personal supplements^a^All participantsNo personal supplements^a^HR95 % CIHR95 % CIHR95 % CIHR95 % CIHR95 % CIMyocardial infarction\<2**1**.**19**0.89,1.59**1**.**30**0.86,1.97**0**.**56**0.14,2.27**1**.**15**0.87,1.51**1**.**21**0.82,1.782--5**0**.**97**0.78,1.21**1**.**04**0.74,1.47**1**.**04**0.66,1.63**1**.**00**0.82,1.23**1**.**11**0.82,1.49\>5**1**.**01**0.80,1.29**1**.**06**0.74,1.50**0**.**89**0.73,1.08**1**.**00**0.80,1.24**1**.**05**0.78,1.41Trend test^b^0.460.490.940.490.54HR in OS/HR in trial^c^0.900.69,1.180.850.61,1.18Overall HR^d^**1**.**03**0.90, 1.19**1**.**11**0.90, 1.37**0**.**90**0.75, 1.09Coronary heart disease^e^\<2**1**.**10**0.85,1.43**1**.**02**0.69,1.49**0**.**49**0.12,2.00**1**.**07**0.83,1.38**0**.**97**0.67,1.382--5**0**.**96**0.79,1.18**1**.**06**0.78,1.45**1**.**00**0.66,1.63**1**.**00**0.83,1.20**1**.**10**0.84,1.44\>5**1**.**05**0.85,1.30**1**.**02**0.75,1.40**0**.**88**0.74,1.05**1**.**03**0.85,1.25**1**.**02**0.78,1.33Trend test^b^0.870.970.880.930.93HR in OS/HR in trial^c^0.860.67,1.100.860.64,1.16Overall HR^d^**1**.**03**0.90, 1.17**1**.**03**0.85, 1.25**0**.**88**0.74, 1.04Total heart disease^f^\<2**1**.**05**0.90,1.21**1**.**00**0.80,1.24**0**.**86**0.50,1.46**1**.**04**0.90,1.20**0**.**99**0.81,1.212--5**1**.**00**0.89,1.12**1**.**05**0.88,1.26**0**.**93**0.73,1.17**1**.**02**0.91,1.13**1**.**05**0.90,1.23\>5**1**.**04**0.91,1.19**0**.**98**0.81,1.20**0**.**87**0.79,0.97**1**.**02**0.91,1.15**0**.**99**0.84,1.16Trend test^b^0.960.910.830.880.91HR in OS/HR in trial^c^0.860.75,0.990.820.74,1.05Overall HR^d^**1**.**02**0.95, 1.11**1**.**02**0.91, 1.14**0**.**87**0.79, 0.96Stroke^g^\<2**0**.**82**0.60,1.12**1**.**11**0.73,1.68**0**.**47**0.12,1.89**0**.**78**0.58,1.05**1**.**00**0.68,1.462--5**1**.**06**0.84,1.34**1**.**17**0.83,1.65**0**.**91**0.57,1.44**1**.**03**0.84,1.27**1**.**16**0.87,1.55\>5**0**.**92**0.73,1.17**1**.**09**0.79,1.52**0**.**93**0.77,1.11**0**.**98**0.80,1.20**1**.**17**0.90,1.54Trend test^b^0.710.930.430.370.53HR in OS/HR in trial^c^0.960.75,1.230.810.60,1.09Overall HR^d^**0**.**95**0.82, 1.10**1**.**12**0.90, 1.39**0**.**92**0.77, 1.09Total cardiovascular disease^h^\<2**0**.**97**0.85,1.11**1**.**02**0.84,1.23**0**.**87**0.55,1.35**0**.**97**0.86,1.10**1**.**02**0.85,1.212--5**0**.**99**0.89,1.10**1**.**03**0.89,1.21**0**.**91**0.74,1.11**1**.**01**0.92,1.10**1**.**04**0.91,1.19\>5**1**.**05**0.93,1.18**1**.**02**0.86,1.21**0**.**86**0.79,0.94**1**.**02**0.93,1.13**1**.**01**0.88,1.16Trend test^b^0.370.970.840.420.93HR in OS/HR in Trial^c^0.850.75,0.960.850.73,0.99Overall HR^d^**1**.**00**0.94, 1.07**1**.**03**0.93, 1.13**0**.**86**0.79, 0.94^a^Women using personal calcium or vitamin D supplements at baseline in the CaD trial are excluded^b^Significance level (*P* value) for test of no HR trend across years from CaD initiation categories, coded as 0, 1, 2, respectively^c^Overall HR in the OS divided by that in the CaD trial. This ratio is used as a residual confounding bias correction factor in the OS, in combined trial and cohort study analyses^d^Overall HR is the hazard ratio estimate when the HR is assumed not to depend on years from CaD initiation^e^Non-fatal MI plus CHD death^f^CHD plus revascularization, angina, and congestive heart failure^g^Combined ischemic and hemorrhagic stroke^h^Total heart disease plus stroke, carotid artery disease, and peripheral vascular disease

Table [4](#Tab4){ref-type="table"} presents corresponding analyses for invasive cancer. Among women with no personal supplements at baseline, there was some evidence for a reduction in breast cancer risk (HR 0.80; 95 % CI, 0.66 to 0.96, *P* = 0.02) and total cancer risk (HR 0.88, 95 % CI, 0.78 to 0.98, *P* = 0.03), with little suggestion of HR time trend and with no support from OS data. These patterns were similar in the trial cohort as a whole, but far from significant.Table 4Hazard ratios and 95 % confidence intervals for calcium plus vitamin D supplementation from the WHI CaD trial and Observational Study according to years from supplement initiation: invasive cancerYears since CaD initiationCaD trialObservational studyCombined trial and OSAll participantsNo personal supplements^a^All participantsNo personal supplements^a^HR95 % CIHR95 % CIHR95 % CIHR95 % CIHR95 % CIColorectal cancer\<2**0**.**89**0.57,1.38**0**.**71**0.35,1.44**0**.**94**0.23,3.87**0**.**92**0.60,1.40**0**.**75**0.39,1.452--5**1**.**00**0.71,1.41**0**.**75**0.45,1.24**0**.**80**0.39,1.65**1**.**02**0.74,1.41**0**.**78**0.50,1.21\>5**1**.**30**0.88,1.92**0**.**99**0.56,1.77**0**.**83**0.60,1.14**1**.**23**0.87,1.74**0**.**90**0.56,1.45Trend test^b^0.190.440.960.260.57HR in OS/HR in trial^d^0.690.45,1.070.940.55,1.59Overall HR^d^**1**.**06**0.85, 1.32**0**.**81**0.58, 1.13**0**.**83**0.61, 1.12Breast cancer\<2**1**.**00**0.79,1.27**0**.**98**0.68,1.42**0**.**90**0.44,1.83**0**.**97**0.78,1.22**0**.**88**0.64,1.222--5**0**.**98**0.82,1.18**0**.**75**0.56,1.00**1**.**05**0.78,1.41**0**.**95**0.81,1.12**0**.**75**0.59,0.95\>5**0**.**89**0.72,1.11**0**.**73**0.52,1.02**1**.**14**1.00,1.30**0**.**95**0.80,1.14**0**.**80**0.62,1.02Trend test^b^0.450.260.420.890.87HR in OS/HR in trial^c^1.180.96,1.451.421.09,1.84Overall HR^d^**0**.**96**0.85, 1.08**0**.**80**0.66, 0.96**1**.**12**0.99, 1.28Total invasive cancer\<2**0**.**96**0.83,1.12**0**.**96**0.76,1.22**0**.**87**0.56,1.36**0**.**95**0.82,1.09**0**.**91**0.74,1.122--5**0**.**94**0.84,1.06**0**.**82**0.69,0.98**0**.**99**0.82,1.20**0**.**94**0.85.1.05**0**.**84**0.73,0.97\>5**0**.**99**0.87,1.13**0**.**89**0.73,1.09**1**.**04**0.95,1.13**0**.**99**0.89,1.11**0**.**90**0.77,1.05Trend test^b^0.770.730.310.480.72HR in OS/HR in trial^d^1.040.91,1.181.150.97,1.35Overall HR^d^**0**.**96**0.89, 1.04**0**.**88**0.78, 0.98**1**.**03**0.95, 1.11^a^Women using personal calcium or vitamin D supplements at baseline in the CaD trial are excluded^b^Significance level (*P* value) for test of no HR trend across years from CaD initiation categories, coded as 0, 1, 2, respectively^c^Overall HR in the OS divided by that in the CaD trial. This ratio is used as a residual confounding bias correction factor in the OS, in combined trial and cohort study analyses^d^Overall HR is the hazard ratio estimate when the HR is assumed not to depend on years from CaD initiation

Table [5](#Tab5){ref-type="table"} presents HRs from the OS for calcium-only and for vitamin D-only supplementation. HRs for calcium plus vitamin D are also repeated from earlier tables for comparative purposes. As mentioned previously, these HRs are subject to residual confounding and other biases, but comparative HRs across supplement types presumably less so. Significant associations were not found for hip fracture or for total fracture for either supplement alone or combined. No associations of calcium or vitamin D with incidence for the specific cancer sites considered or for total invasive cancer were suggested by these Table [5](#Tab5){ref-type="table"} analyses. A non-significant early elevation in MI incidence with vitamin D is not precisely estimated and is not apparent with the combination of calcium and vitamin D. HR estimates were below one (*P* \< 0.05) for calcium alone in relation to MI and CHD, and as previously mentioned, for CaD in relation to total heart disease.Table 5Hazard ratios and 95 % confidence intervals for supplementation of calcium only and vitamin D only and for calcium and vitamin D combined from the WHI Observational Study, according to years from supplement initiationYears from Supplement InitiationCalcium onlyVitamin D onlyCaDCalcium onlyVitamin D onlyCaDHR95 % CIHR95 % CIHR95 % CIHR95 % CIHR95 % CIHR95 % CIHip fractureTotal fracture\<2**2**.**85**0.67,12.12**2**.**51**0.34,18.60**1**.**41**0.44,4.57**0**.**69**0.37,1.29**1**.**53**0.82,2.86**0**.**89**0.61,1.312--5**0**.**60**0.19,1.89**1**.**44**0.45,4.56**1**.**22**0.71,2.10**0**.**93**0.75,1.16**1**.**19**0.88,1.61**1**.**05**0.91,1.22\>5**0**.**82**0.58,1.15**1**.**17**0.73,1.86**0**.**84**0.66,1.07**1**.**00**0.91,1.09**1**.**02**0.88,1.18**1**.**08**1.01,1.14Trend test^a^0.490.480.140.260.150.42Overall HR^b^**0**.**82**0.59, 1.14**1**.**23**0.80, 1.88**0**.**88**0.70,1.11**0**.**99**0.91,1.07**1**.**06**0.93,1.20**1**.**07**1.01,1.14Myocardial infarctionCoronary heart disease\<2**0**.**85**0.21,3.48**1**.**72**0.42,7.06**0**.**56**0.14,2.27**0**.**77**0.19,3.13**1**.**59**0.39,6.48**0**.**49**0.12,2.002--5**0**.**87**0.44,1.69**1**.**28**0.57,2.89**1**.**04**0.66,1.63**0**.**96**0.54,1.72**1**.**07**0.48,2.41**1**.**00**0.66,1.53\>5**0**.**71**0.53,0.97**0**.**99**0.67,1.47**0**.**89**0.73,1.08**0**.**74**0.56,0.97**1**.**02**0.72,1.45**0**.**88**0.74,1.05Trend test^a^0.600.380.940.530.610.88Overall HR^b^**0**.**74**0.56, 0.97**1**.**06**0.75, 1.51**0**.**90**0.75,1.09**0**.**74**0.58,0.95**1**.**04**0.76,1.43**0**.**88**0.74,1.04Total heart diseaseStroke\<2**1**.**07**0.57,2.00**1**.**32**0.59,2.96**0**.**86**0.50,1.46**0**.**84**0.21,3.41NA^c^**0**.**47**0.12,1.892--5**1**.**05**0.78,1.42**0**.**83**0.51,1.36**0**.**93**0.73,1.17**1**.**04**0.58,1.86**0**.**77**0.29,2.07**0**.**91**0.57,1.44\>5**0**.**95**0.82,1.10**0**.**97**0.78,1.20**0**.**87**0.79,0.97**0**.**81**0.62,1.07**0**.**82**0.55,1.23**0**.**93**0.77,1.11Trend test^a^0.470.820.830.470.450.28Overall HR^b^**0**.**95**0.83, 1.08**0**.**96**0.79, 1.16**0**.**87**0.79,0.96**0**.**84**0.66,1.07**0**.**80**0.55,1.15**0**.**92**0.77,1.09TOTAL CARDIOVASCULAR DISEASECOLORECTAL CANCER\<2**0**.**99**0.57,1.72**1**.**09**0.52,2.30**0**.**87**0.55,1.35**1**.**03**0.14,7.47NA^c^**0**.**94**0.23,3.872--5**1**.**02**0.78,1.32**0**.**90**0.60,1.34**0**.**91**0.74,1.11**1**.**05**0.42,2.58**0**.**95**0.23,3.88**0**.**80**0.39,1.65\>5**0**.**89**0.79,1.01**0**.**92**0.76,1.10**0**.**86**0.79,0.94**1**.**01**0.66,1.55**0**.**64**0.28,1.46**0**.**83**0.60,1.14Trend test^a^0.310.810.840.960.910.96Overall HR^b^**0**.**89**0.80,1.60**0**.**92**0.78,1.09**0**.**86**0.79,0.94**1**.**02**0.69,1.51**0**.**67**0.33,1.36**0**.**83**0.61,1.12Breast cancerTotal invasive cancer\<2**0**.**44**0.11,1.76**1**.**74**0.55,5.48**0**.**90**0.44,1.83**0**.**43**0.18,1.04**0**.**95**0.39,2.30**0**.**87**0.56,1.362--5**1**.**15**0.76,1.72**1**.**18**0.85,2.71**1**.**05**0.78,1.41**1**.**13**0.88,1.46**0**.**81**0.51,1.29**0**.**99**0.82,1.20\>5**1**.**18**0.98,1.42**1**.**11**0.62,1.23**1**.**14**1.00,1.30**1**.**12**0.99,1.26**1**.**05**0.87,1.28**1**.**04**0.95,1.13Trend test^a^0.300.070.420.180.400.31Overall HR^b^**1**.**15**0.97,1.37**1**.**01**0.75,1.34**1**.**12**0.99.1.28**1**.**10**0.98,1.22**1**.**01**0.85,1.20**1**.**03**0.95,1.11Death\<2**0**.**32**0.05,2.31**1**.**31**0.32,5.31**1**.**49**0.79,2.832--5**1**.**05**0.69,1.60**0**.**78**0.39,1.57**0**.**85**0.61,1.18\>5**0**.**93**0.80,1.09**1**.**09**0.87,1.35**0**.**95**0.85,1.06Trend test^a^0.810.600.71Overall HR^b^**0**.**94**0.81,1.09**1**.**06**0.86,1.30**0**.**95**0.85,1.06^a^Significance level (*P* value) for test of no HR trend across years from CaD initiation categories, coded as 0, 1, 2, respectively^b^Overall HR is the hazard ratio estimate when the HR is assumed not to depend on years from CaD initiation^c^NA---too few events for reliable HR calculation

Data on adherence to assigned supplement category is important for the interpretation of Table [5](#Tab5){ref-type="table"} analyses. Following the baseline assessment, data on supplement use in the OS was collected only in conjunction with a clinic visit 3 years later. Of the OS women using calcium plus vitamin D at baseline, a substantial 80.9 % reported continued use 3 years later, with 10.9 % stopping use of both of these supplements, 6.9 % moving to calcium-only, and 1.4 % moving to vitamin D-only supplements. In contrast among baseline calcium-only users, a remarkable 57.1 % had moved to CaD preparations by 3 years later, with only 23.7 % still using calcium only, and 17.6 % had stopped using either supplement. Similarly 56.5 % of baseline vitamin D users had moved to CaD by 3 years later, with only 16.4 % still using vitamin D only. Equally impressive, only 49.9 % of baseline non-users of these supplements retained that status 3 years later, with 38.7 % becoming CaD users. It is evident that the contrasts presented in Table [5](#Tab5){ref-type="table"} primarily pertain to CaD use, and even then the non-user control group evidently becomes quite contaminated over the follow-up period.

Table [6](#Tab6){ref-type="table"} shows HR estimates from the CT using follow-up data from each participating woman only during the period of time that she remained adherent to her assigned active CaD or placebo pills. Among adherent women, hip fracture risk was lower in the active treatment group both in the overall trial cohort (*P* = 0.05), and in the subset of women without personal supplements (*P* = 0.04). The HR (95 % CI) among adherent women not using personal supplements was an impressive 0.24 (0.07, 0.84) following 5 or more years of use among women not using personal supplements. The myocardial infarction HR (95 % CI) was a non-significant 1.18 (0.88, 1.59) among women not using personal calcium or vitamin D. In contrast, breast and total invasive cancer risks were reduced (both *P* = 0.01) among women adherent to CaD in these analyses. Analyses that incorporated inverse adherence probability weights were similar with overall test *P* values among women not using personal supplements of 0.02 for hip fracture, 0.98 for MI, 0.06 for invasive breast cancer, and 0.01 for total invasive cancer.Table 6Hazard ratios and 95 % confidence intervals for calcium and vitamin D supplementation in the WHI CaD trial according to duration of supplementation among women adherent to their assigned study pillsDuration of CaD supplementationAll participantsNo personal supplementsAll participantsNo personal supplementsHR95 % CIHR95 % CIHR95 % CIHR95 % CIHip fractureTotal fracture\<2**0**.**62**0.33,1.15**0**.**88**0.32,2.43**0**.**95**0.83,1.08**0**.**87**0.70,1.062--5**0**.**83**0.50,1.37**0**.**66**0.28,1.52**0**.**90**0.79,1.03**0**.**91**0.73,1.13\>5**0**.**73**0.44,1.23**0**.**24**0.07,0.84**0**.**98**0.82,1.16**0**.**95**0.71,1.27Trend test^a^0.740.120.890.61Overall HR^b^**0**.**73**0.54, 1.00**0**.**55**0.32, 0.97**0**.**94**0.86, 1.02**0**.**90**0.78, 1.03Myocardial infarctionCoronary heart disease\<2**1**.**23**0.90,1.69**1**.**37**0.86,2.18**1**.**21**0.90,1.62**1**.**14**0.74,1.762--5**1**.**07**0.78,1.49**1**.**35**0.81,2.26**1**.**01**0.74,1.36**1**.**26**0.78,2.01\>5**0**.**82**0.55,1.21**0**.**78**0.43,1.41**0**.**88**0.61,1.26**0**.**82**0.47,1.41Trend test^a^0.120.170.170.40Overall HR^b^**1**.**06**0.87, 1.29**1**.**18**0.88, 1.59**1**.**04**0.87, 1.25**1**.**08**0.82, 1.42Total heart diseaseStroke\<2**1**.**06**0.89,1.25**1**.**05**0.82,1.34**0**.**81**0.57,1.14**1**.**01**0.63,1.642--5**1**.**01**0.85,1.19**1**.**00**0.77,1.31**1**.**19**0.85,1.67**1**.**73**0.99,3.01\>5**1**.**04**0.84,1.30**0**.**92**0.66,1.29**0**.**88**0.57,1.36**0**.**92**0.48,1.76Trend test^a^0.870.560.600.96Overall HR^b^**1**.**03**0.93, 1.15**1**.**00**0.86, 1.18**0**.**96**0.78, 1.19**1**.**18**0.86, 1.62Total cardiovascular diseaseColorectal cancer\<2**0**.**98**0.85,1.14**1**.**04**0.84,1.29**0**.**91**0.56,1.47**0**.**73**0.34,1.602--5**1**.**04**0.89,1.20**1**.**07**0.84,1.34**1**.**01**0.62,1.66**0**.**92**0.44,1.93\>5**1**.**06**0.88,1.29**0**.**98**0.73,1.31**1**.**10**0.59,2.07**0**.**71**0.27,1.88Trend test^a^0.490.770.630.98Overall HR^b^**1**.**02**0.93, 1.12**1**.**04**0.90, 1.19**0**.**99**0.73, 1.34**0**.**80**0.50, 1.27Breast cancerTotal invasive cancer\<2**0**.**96**0.73,1.27**0**.**90**0.58,1.39**0**.**97**0.82,1.14**0**.**94**0.71,1.232--5**0**.**85**0.66,1.10**0**.**60**0.39,0.92**0**.**86**0.74,1.02**0**.**70**0.53,0.92\>5**0**.**88**0.63,1.24**0**.**67**0.39,1.17**0**.**95**0.77,1.18**0**.**79**0.56,1.11Trend test^a^0.640.350.810.35Overall HR^b^**0**.**90**0.76, 1.06**0**.**71**0.55, 0.93**0**.**92**0.83, 1.02**0**.**80**0.68, 0.95Death\<2**0**.**78**0.57,1.08**0**.**69**0.41,1.162--5**0**.**81**0.63,1.04**0**.**82**0.54,1.26\>5**1**.**06**0.80,1.41**1**.**02**0.65,1.59Trend test^a^0.140.26Overall HR^b^**0**.**88**0.75, 1.03**0**.**85**0.65, 1.11^a^Significance level (*P* value) for test of no HR trend across years from CaD initiation categories, coded as 0, 1, 2, respectively^b^Overall HR is the hazard ratio estimate when the HR is assumed not to depend on duration from supplementation

For completeness, corresponding analyses were also carried out for the complementary subset of 20,275 CT women who reported taking personal supplements of calcium or vitamin D, or both, at the time of WHI enrollment. Overall, HRs (95 % CI) in this subset were as follows: hip fracture 0.90 (0.69,1.17), total fracture 0.95 (0.87,1.02), MI 0.97 (0.80,1.17), CHD 1.01 (0.85,1.20), total heart disease 1.04 (0.94,1.16), stroke 0.83 (0.67,1.01), total cardiovascular disease 0.99 (0.90,1.08), colorectal cancer 1.32 (0.98, 1.79), breast cancer 1.09 (0.93,1.28), total invasive cancer 1.04 (0.94,1.15), and death 0.91 (0.79,1.04). None of these HRs differ significantly from unity, though for some outcomes, there is a significant HR difference between the personal supplements and no personal supplements subsets, including stroke (*P* = 0.04), colorectal cancer (*P* = 0.04), breast cancer (*P* = 0.01), and total invasive cancer (*P* = 0.03).

Among women who were adherent to study pills, the overall HRs (95 % CIs) in the personal supplements user subset were as follows: hip fracture 0.85 (0.58,1.24), total fracture 0.97 (0.87,1.07), MI 0.96 (0.74,1.26), CHD 1.00 (0.79,1.28), total heart disease 1.05 (0.91,1.21), stroke 0.81 (0.60,1.08), total cardiovascular disease 1.01 (0.89,1.14), colorectal cancer 1.17 (0.78,1.73), breast cancer 1.04 (0.85,1.29), total invasive cancer 1.02 (0.90,1.17), and death 0.91 (0.74,1.11). There was significant adherent HR variation between the personal supplements and no personal supplements subsets only for breast cancer (*P* = 0.03) and total invasive cancer (*P* = 0.03) in these adherence-adjusted analyses.

Concerning urinary tract stones, as previously reported \[[@CR1], [@CR7]\] 449 women (0.35 %) in the group randomized to CaD and 381 women (0.30 %) in the placebo group developed urinary tract stones during the trial intervention period, leading to an HR (95 % CI) of 1.17 (1.02, 1.34). Among adherent women, the HR (95 % CI) was 1.21 (0.98, 1.50). These analyses were repeated here, separately for the no personal supplements and personal supplements groups.

In the no personal supplements subset, the HR (95 % CI) was 1.08 (0.88,1.32) based on 199 women developing urinary tract stones in the active treatment group and 180 in the placebo group. The corresponding HR (95 % CI) in the personal supplements subset was 1.23 (1.01, 1.48) based on 239 and 197 women with stones in the active and placebo groups. The HRs did not differ significantly (*P* = 0.39) between the two subsets. Among adherent women, the HR (95 % CI) was 1.21 (0.87, 1.69) in the no personal supplements group and 1.19 (0.89, 1.58) in the personal supplements group, with no evidence (*P* = 0.87) for difference between the HRs for adherent women between the two subsets.

Subset analyses by age group or by prior CVD history were generally similar to those for the overall cohorts for the various outcomes considered above and are not shown.

Discussion {#Sec7}
==========

Our further analyses of WHI calcium and vitamin D trial data, through the end of the intervention period, along with corresponding and combined analyses using the WHI observational study, yields few clear clinical effects for daily 1,000 mg calcium plus 400 IU of vitamin D.

The strongest evidence for benefit is for hip fracture where calcium and vitamin D supplementation yielded a noteworthy reduction after 5 years of treatment among women not taking personal supplements, with HR (95 % CI) of 0.62 (0.38, 1.00). It is important to note that hip fracture was the sole primary outcome in the CaD trial, reducing multiple testing limitations. Nevertheless, a cautious interpretation is needed since this is a finding in the no personal supplements subset, while the corresponding overall trial result (HR of 0.82, 95 % CI of 0.61 to 1.12) is not significant. However, the likelihood of a hip fracture risk reduction is enhanced by a significant (*P* = 0.02) trend of reducing HR with duration of supplementation in the no personal supplements group and by nominally significant risk reductions over the entire follow-up period among adherent women, both in the overall trial cohort and in the no personal supplements subset (Table [6](#Tab6){ref-type="table"}). For example, these adherence-adjusted analyses yield an HR (95 % CI) of 0.24 (0.07, 0.84) following 5 or more years of use among women in the no personal supplements group, suggesting that the public health implications of supplementation could be substantial. Moreover, the biological plausibility of this finding is also supported by higher (*P* \< 0.01) hip bone mineral density (BMD) in the active treatment versus placebo group at 2, 5, and 8 years of follow-up \[[@CR1]\]. Supplementary Figure [1](#MOESM2){ref-type="media"} shows average hip, spine, and whole body BMD at baseline, and at 2, 5, and 8 years later, by randomization group, overall, and in the subset of women not using personal supplements, with and without restriction to women adhering to assigned study pills. A larger hip BMD in the intervention group is evident overall, and among women not taking personal supplements, and the difference is enhanced among adherent women.

WHI data provide little support for an influence of calcium and vitamin D supplementation on coronary heart disease risk or cardiovascular disease risk more generally. Women randomized to CaD do not have a significantly elevated risk of MI, CHD, total heart disease, stroke or total cardiovascular disease, either overall or in the subset not using supplements at baseline. Furthermore, any suggestion of an early MI elevation is dampened by multiple testing considerations, since none of the several cardiovascular disease categories considered were among the designated primary or secondary trial outcome and any such suggestion was not enhanced by restriction to women who adhered to study medications. Also, there was no suggested MI elevation in the OS. Moreover, in the analyses of 754 women in the CaD trial who underwent cardiac CT scans for assessment of coronary artery calcium (CAC) scores at trial completion, no association between CaD supplementation and CAC was observed, irrespective of baseline intake of calcium and/or vitamin D \[[@CR31]\]. However, given concern about an elevation in MI with calcium use based on other data sources \[[@CR8]\], one should keep in mind the possibility of an early MI elevation, but this hypothesis derives little support from WHI data.

The analyses of CaD trial data suggest possible reductions for invasive cancer with supplementation \[[@CR3], [@CR8]\]. Such HR reductions are nominally significant for invasive breast cancer (*P* = 0.02) and for total invasive cancer (*P* = 0.03) among women not using personal supplements, and these reductions persisted following restriction to adherent women. However, corresponding HR reductions were not significant for the trial cohort as a whole. The fact that HRs for both breast cancer and total cancer differed significantly between the personal supplements and no personal supplements groups could reflect HRs that are below unity at lower calcium and vitamin D doses, and that flatten out at larger doses so that women using personal supplements may have already achieved any cancer risk reduction from supplementation, with little or no further benefit from further supplementation. While this possibility is intriguing, and potentially of public health importance, breast and total cancer were not among the designated primary or secondary outcomes for the CaD, so multiple testing considerations, in conjunction with subset analysis and other \[[@CR3]\] considerations cause us to take a cautious interpretation of these analyses. Hence, we regard the WHI data as merely suggestive of invasive breast and total invasive cancer risk reduction with available data.

Consistent with our previous report \[[@CR7]\], we find no statistically significant association between CaD supplementation and death in the CaD trial overall or in the subgroup not using personal supplements. There was no evidence in either the CaD trial or the OS that long-term (≥5 years) CaD supplementation reduced the risk of death. Specifically, the CaD intervention did not affect death from coronary heart disease where the hazard ratio was 0.99 (95 % CI, 0.71, 1.38) \[[@CR7]\].

With this background, the only documented risk associated with the randomized intervention in the CaD trial is a modest elevation (HR of 1.17, 95 % CI from 1.02 to 1.34) in urinary tract stone occurrence that did not differ significantly between the personal supplements and no personal supplements subsets.

Observational data have several limitations in addressing these types of research questions. For outcomes, such as hip fractures and heart disease, where calcium and/or vitamin D from foods or supplements may have developed a reputation as potential disease preventatives, observational studies not only need to control for standard confounding factors, but also for factors related to confounding by indication since persons at elevated risk for these diseases may self-select, or preferentially be prescribed, these supplements. On the other hand, women using dietary supplements are typically health conscious and may have favorable risk factor profiles for some study diseases. The extent to which confounding control efforts are adequate in such challenging settings is usually unknown. In fact, we see evidence of differing HRs for calcium plus vitamin D from the CaD trial and the OS in Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, and [4](#Tab4){ref-type="table"} (i.e., HR in OS/HR in CT differs from unity) for several outcomes including total fracture, total heart disease, total cardiovascular disease, and breast cancer. Even though some of these differences may arise from differential adherence to supplementation, they reinforce the need for a cautious approach to interpreting observational associations of this type. Here, inclusion of the OS data did not lead to any new findings but did contribute to evidence for a hip fracture reduction, via our conservative combined clinical trial and observational study data analyses.

Even though there is intense interest in the health effects of supplementation using higher doses than 400 IU/day of vitamin D, the WHI cohorts simply do not have enough women using higher doses to attempt any meaningful analyses.

In summary, WHI clinical trial data are mostly null or inconclusive concerning the health effects of calcium and vitamin D supplementation. Compared to previous WHI reports, the analyses presented here include a focus on whether or not women were using personal supplements at the time of WHI enrollment and a focus on temporal HR patterns across the trial intervention period, leading to more compelling evidence for a hip fracture risk reduction benefit that is somewhat offset by a previously reported elevation in urinary tract stones. Ultimate health benefits versus risks assessment for this intervention could be favorably affected by a reduction in invasive cancer, though evidence is only suggestive at present, while data from other sources suggesting adverse cardiovascular effects of calcium supplementation do not receive support from WHI data. Decisions concerning supplementation with this combination may depend on many factors, including age and sex, and importantly, risk for outcomes affected by CaD. Given the widespread use of these supplements in the USA and elsewhere, it will be important to continue to acquire data to refine estimates of health benefits and risks among postmenopausal women, and other societal groups, and to extend results to other supplementation doses.
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Supplementary Table 1Modeled regression variables by clinical outcome included in WHI Observational Study component of analyses. Additionally, in both the Clinical Trial and Observational Study, baseline Cox model hazard rates are stratified on cohort (CT versus OS), baseline age (5-year categories), and current use of postmenopausal estrogens and of estrogens plus progestins. Additional modeled regression variables in both the CT and OS included prior use of estrogens and of estrogens plus progestins, duration of any such prior use, and FFQ estimates of usual dietary consumption of calcium and vitamin D. (DOCX 20 kb)
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